Self-Injection Device Market Size, Share, and COVID-19 Impact Analysis By Product Type (Pen Injectors, Autoinjectors, Needle Free Injectors, and Others), By Type (Disposable and Reusable), By Application (Pain Management, Diabetes, Anaphylaxis, and Others), By Distribution Channel (Hospital Pharmacies and Retail & Online Pharmacies), and Regional Forecast, 2024-2032

Self-injection devices are patient-controlled injectors, ergonomically designed for patient self-administration of drugs and medication through the subcutaneous or intramuscular route. These devices enable patients to automatically inject a wide range of high-volume or highly viscous medications over time in home settings.

The prevalence of chronic disorders such as diabetes, cancer and autoimmune diseases is increasing globally. According to statistics published by International Diabetes Federation (IDF) in 2021, approximately 537.0 million adults (20-79 years) were suffering from diabetes across the globe. As per similar estimates, the total number of patients suffering from diabetes is projected to rise to 643.0 million by 2030 and 783.0 million by 2045.

Also, development and advancements in combination medicines, biologics, and biosimilar compounds are on the rise by key players. Furthermore, the surge in advancements of these medications has led to the demand for innovative and cost-effective delivery methods, such as autoinjectors, pen injectors, and other devices that support patients’ treatment and lifestyle needs.

Thus, pharmaceutical companies are now introducing self-administration therapies to ensure patient dose compliance and administration ease. Several self-injection devices, such as jet injectors, pens, auto-injectors, and pre-filled syringes, are being developed by leading players for delivering medications, such as injectable vaccines and chronic disease medications. Also, the rising adoption of safe and cost-effective drug administration among patients in home settings will boost the demand for these devices, further propelling the market growth. However, a lack of awareness of self-injection devices across developing and low-income countries will restrain the market growth.

Impact of COVID-19 on the Self-injection Devices Market

The COVID-19 pandemic substantially impacted the market for self-injection devices. The market growth was affected due to fewer patients seeking a diagnosis and treatment at hospitals for non-urgent disorders. Moreover, the COVID-19 pandemic caused supply chain disruptions, and a decline in the production and demand of self-injection devices such as epinephrine autoinjectors.

• According to Viatris annual report estimates in 2020, the EpiPen autoinjector sales decreased from USD 324.0 million in 2019 to 307.6 million in 2020.

However, the pandemic positively impacted the market through high patient awareness and demand for devices such as pen injectors in the treatment of chronic conditions such as diabetes in home settings to refrain from COVID-19 infection, which helped the market grow steadily.

• According to Ypsomed AG estimates in 2020, the delivery devices reported a sales growth from USD 211.9 million in 2019 to USD 233.1 million in 2020.

Key Insights

The report will cover the following key insights:

• Prevalence of Key Conditions, by Key Countries/ Region, 2022.


• Technological Advancements in Drug Delivery Systems.


• Recent Product Launches, By Key Players.


• Key Industry Developments – Partnerships, Mergers and New Product Launches, etc.


• Impact of COVID-19 on the Market.

Analysis by Product Type:

Based on the product type, the market is segmented into pen injectors, autoinjectors, needle free injectors, and others. The pen injectors segment is expected to grow at the highest CAGR owing to the increasing demand for insulin administration among diabetic patients and rising patient preference for pen injectors in diabetes management at home settings. Also, increasing initiatives by key players to launch technologically advanced devices to expand their existing product portfolio globally will further augment segment growth.

• In February 2023, Phillips-Medisize, a pioneer in manufacturing diagnostic and MedTech devices, announced the expansion of its product portfolio with the introduction of a disposable pen injector. This device is an addition to Phillips-Medisize's expanding product and platform portfolio that will empower biopharma companies to accelerate the rollout of novel and generic drug treatments at significant economies of scale.

Regional Analysis:

To gain extensive insights into the market, Request for Customization

North America is anticipated to lead the self-injection devices market with a significant revenue share and is expected to dominate the market during the forecast period. The growth is mainly attributed to the rising prevalence of chronic diseases such as cancer and rheumatoid arthritis, and the high presence of major market players, such as Ypsomed AG and Viatris, among others across the region. Moreover, rising strategic collaborations among the key players to introduce advanced devices in North America will further propel regional growth.

• In January 2022, Innovation Zed Ltd., in partnership with SHL Medical AG to develop connected pen injector solutions, announced the launch of InsulCheck DOSE. This connected device transforms traditional pen injectors into smart solutions to support the monitoring of disease treatment.

Key Players Covered:

The report will include key players such as Ypsomed AG, Recipharm AB, Phillips-Medisize, SHL Medical AG, Teva Pharmaceuticals, Inc., Gerresheimer AG, Pfizer, Inc., Insulet Corporation, Halozyme, Inc., and other prominent players.

Segmentation

Key Industry Developments

• May 2022: Jabil Healthcare, a division of Jabil Inc., announced the launch of the Qfinity autoinjector platform, a reusable and modular solution for subcutaneous drug self-administration at a lower cost, supporting the emerging prioritization of sustainable drug delivery within the pharmaceutical industry.


• June 2022: NovaXS Biotech announced that it unveiled the new prototype for its needle-free injection therapy smart medical device.


• In October 2022, Ypsomed AG introduced a new autoinjector platform YpsoMate 5.5, for liquid medications. This device is the latest addition to the growing YpsoMate portfolio of devices.


• October 2022: BIOCORP, a French company specialized in manufacturing innovative medical devices, and Merck KGaA entered into an agreement to develop and supply a specific version of Mallya device as an accessory for one of Merck KGaA drug delivery devices.